Veraxa Biotech AG - Post de-SPAC

VRXANasdaq Switzerland Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$152.720 M

$1.08 -4.42%

Close of 7 Oct 2026

As of 7 Oct 2026, Veraxa Biotech AG - Post de-SPAC (VRXA) has a market capitalization of $152.7M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

—

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Other share classes

Veraxa Biotech AG - Post de-SPAC lists more than one class of stock. Company figures above cover all classes combined.

VRXAW

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#277Jyong BiotechMENS$153.6M
#278Alx OncologyALXO$153.5M
#279Veraxa Biotech AG - Post de-SPACVRXA$152.7M
#280Kazia TherapeuticsKZIA$144.0M
#281Korro BioKRRO$143.7M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Veraxa Biotech AG - Post de-SPAC, worth $82.7K. Grants and option exercises are excluded.

Oliver Rolf Baumann$75.0K
50,000 shares at $1.50 on 27 Aug 2026 · filed 31 Aug 2026
Christoph Rudiger AntzChief Executive Officer$7.65K
5,000 shares at $1.53 on 27 Aug 2026 · filed 31 Aug 2026

What if Veraxa Biotech AG - Post de-SPAC were worth as much as…

Open the what-if tool →

Gold $28.8T

$203,591.54

Per share 188,511× higher

Bitcoin $1.67T

$11,811.57

Per share 10,937× higher

Nvidia $5.77T

$40,773.45

Per share 37,753× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Veraxa Biotech AG - Post de-SPAC are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 8 Oct 2026. Read the methodology.